What is a feature table in a Sequence Listing XML and why is it important?
A feature table in a Sequence Listing XML is a crucial component that provides information about various regions within a particular sequence. As stated in MPEP 2413.01(g): “A feature table is required for every sequence, except for any intentionally skipped sequence, in which case it must not be included. The feature table is contained in…
Read MoreWhat is the feature table in a “Sequence Listing XML”?
The feature table in a “Sequence Listing XML” contains information on the location and roles of various regions within a particular sequence. As stated in MPEP 2413.01(g): “A ‘feature table’ contains information on the location and roles of various regions within a particular sequence. A feature table is required for every sequence, except for any…
Read MoreAre there any exceptions to the requirement for incorporating the “Sequence Listing XML” by reference?
Yes, there is an exception to the requirement for incorporating the “Sequence Listing XML” by reference. According to MPEP 2413.04 and 37 CFR 1.834(c)(2): “If the ‘Sequence Listing XML’ required by § 1.831(a) is submitted in XML file format via the USPTO patent electronic filing system or on a read-only optical disc (in compliance with…
Read MoreWhat does “enumeration of its residues” mean in the context of Sequence Listing XML?
According to MPEP 2412.02(a), “enumeration of its residues” refers to the disclosure of a nucleotide or amino acid sequence in a patent application by listing each residue of the sequence in order. The MPEP cites 37 CFR 1.831(d), which states: “Enumeration of its residues” means disclosure of a nucleotide or amino acid sequence in a…
Read MoreWhen is an English translation of a “Sequence Listing XML” required?
An English translation of a “Sequence Listing XML” is required when the original submission contains language-dependent free text elements in a language other than English. This requirement is based on 37 CFR 1.52(b)(1)(ii), which states: “[The application] must: Be in the English language or be accompanied by a translation of the application and a translation…
Read MoreWhen did the requirement for including an XML declaration in Sequence Listing XML become effective?
The requirement for including an XML declaration in Sequence Listing XML became effective for patent applications filed on or after July 1, 2022. As stated in MPEP 2413.01(c): This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR…
Read MoreWhen did the requirements for the Title Element in Sequence Listing XML come into effect?
The requirements for the Title Element in Sequence Listing XML came into effect on July 1, 2022. According to the editor’s note in MPEP 2413.01(i): “This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” This means…
Read MoreWhen did the requirements for Sequence Listing XML format come into effect?
The requirements for the Sequence Listing XML format came into effect for certain patent applications filed on or after July 1, 2022. According to the editor’s note in MPEP 2412.05(a): “[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as…
Read MoreWhat should I do if my Sequence Listing XML contains errors?
If your Sequence Listing XML contains errors, the USPTO will notify you through a PAIR document titled “Computer Readable Form (CRF) for Sequence Listing – Defective.” According to MPEP 2416, you must provide: A replacement “Sequence Listing XML” part of the disclosure A statement identifying the location of all additions, deletions, or replacements of sequence…
Read MoreWhat are the consequences of omitting the XML declaration in a Sequence Listing XML?
Omitting the XML declaration in a Sequence Listing XML can have serious consequences for a patent application. While not explicitly stated in MPEP 2413.01(c), the implications can be inferred: The application may be considered non-compliant with 37 CFR 1.833(b)(2)(i) It may lead to processing errors or misinterpretation of the sequence data The patent office may…
Read More